Daily News Podcast

Esketamine gets the green light for depression

Publish date: March 7, 2019

 

The FDA approves intranasal esketamine for refractory major depressive disorder. A behavioral intervention improves physical activity in patients with diabetes. Groups of physicians produce more accurate diagnoses than individuals. And there’s a new target for reducing sodium consumption.
Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

Recommended Reading

A prescription for medicine’s gender inequality
MDedge Internal Medicine
Parental leave inequities: Kirti Magudia and Thomas Ng, Part I
MDedge Internal Medicine
Peripheral perfusion fails septic shock test, but optimism remains
MDedge Internal Medicine
Trump targets abortion by denying family planning funds
MDedge Internal Medicine
Online vitriol’s expansion into doctor discussion sites
MDedge Internal Medicine
Caring for aging HIV-infected patients requires close attention to unrelated diseases
MDedge Internal Medicine
Will having fewer primary care physicians shorten Americans’ lifespans?
MDedge Internal Medicine
Cancer-battling breath, Zombie Bambi, and hops as health food
MDedge Internal Medicine
Patients who want to make you retire, and how to cope
MDedge Internal Medicine
Infective endocarditis isn’t what it used to be
MDedge Internal Medicine